reports hero background
Updated: Aug 17, 2026
NVS Logo

Novartis

NYSE:NVS·Stock Analysis Report
Day Range
$155.87 - $159.33
Market Cap
287.46B
P/E Ratio
22.7915
Avg Value
$146.02
Year Range
$121.58 - $170.46
$156.24-$4.07 (-2.54%)
1
General Information
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic.

It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

2
Novartis (NVS) Stock Graph
3
How We Grade Novartis (NVS)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade Novartis (NVS) across the board compared to its closest peers.

4
Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

26.82

Growth measures a stock's combined historical expansion in earnings and revenue across multiple time periods, with emphasis on both long-term trends and recent performance.

21.96

Value is a percentile-ranked composite metric that evaluates a stock's relative worth by comparing its market price to fundamental measures of the company's assets, earnings, sales, and operating performance.

Momentum measures a stock's relative strength based on its price movement patterns and volatility over multiple timeframes, ranked as a percentile against other stocks.

70.16

Quality is a composite ranking that evaluates a company's operational efficiency and financial health by analyzing historical profitability metrics and fundamental strength indicators on a percentile basis relative to peers.

Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
5
Peer Ratings

See how Novartis compares to its peers in these key performance metrics from Benzinga Rankings.

Top Peers
Value
Quality
Growth
Momentum
Short
Medium
Long
AZNAstraZeneca
24.02
N/A
80
81.54
MRKMerck & Co
9.93
83.11
12.92
91.05
NVONovo Nordisk
52.34
94.32
83.08
18.33
PFEPfizer
29.18
38.79
2.75
46.07
Short: price trend over the last couple of months
Medium: price trend over the last couple of quarters
Long: price trend over the past year
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
6
Valuation

Earnings History (3 years)

It is important to look at a companies earnings history to see not only if they are profitable, but if their earnings are growing.
As you can see from the chart above, NVS's earnings have increased for the past three years, this is a positive sign for the stock.
7
Financial Health
What is the current state of the company's financial situation?

We measure the health of a company based on how profitable they are and their ability to cover both their short-term and long-term debts. The key indicators that we use are the Operating Margin, Quick Ratio, and Debt-to-Equity ratio relative to the companies peers

Operational Margin 0.3177

The operating margin measures how much profit a company makes after it spends money on wages, materials or other administrative expenses but before interest and taxes. It is a good representation of how efficiently a company is able to generate profit from its core operations.

Quick Ratio 0.5526

The quick ratio measures how much of a company's debt, that is due in less than 1 year, can be covered using its cash equivalents, marketable securities, and money that is currently owed to them (accounts receivables).

A company with a quick ratio of less than 1.00 does not, in many cases, have the capital on hand to meet its short-term obligations if they were all due at once, while a quick ratio greater than one indicates the company has the financial resources to remain solvent in the short term.

Debt-to-Equity 1.9279

Debt-to-equity is calculated by dividing a company's total liabilities by its shareholders equity. It is a measure of the degree to which a company is financing its operations through debt versus wholly owned funds. Generally speaking, a D/E ratio below 1.0 would be seen as relatively safe, whereas ratios of 2.0 or higher would be considered risky.

The chart above shows Novartis (NVS) operating margin, quick ratio, and debt-to-equity ratio compared to its peers. The black markers represent the peer averages for each ratio and the blue bars represent Novartis (NVS) ratio values.
8
Dividend
There are few things we like to see when evaluating the quality of a company's dividend history and future

Ideally, we would like to see a company have a long history of consistently high dividend payouts that have grown at a consistent rate. From here we want to be confident that this sort of dividend growth and consistency will persist into the future.

The chart below shows the historical trend in Novartis (NVS) dividend yield on an annual basis.

42.48%
Novartis (NVS) saw a increase in its dividend yield since 2022
9
Past Performance
How has Novartis (NVS) performed over the past 5 years?

The two main factors that we consider when analyzing past performance is overall return and volatility

Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.

This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.

Novartis (NVS) sharpe ratio over the past 5 years is 1.1477 which is considered to be above average compared to the peer average of 0.8684

10
Analyzing Novartis (NVS) Recent Options Activity
Below, you can see the trend in options sentiment over the past 30 days.

Based on our data, NVS's options trades have recently carried more negative sentiment than positive.

11
Company Financials
INCOME STATEMENT
The income statement also known as the profit and loss statement, primarily focuses on the company's revenues and expenses during a particular period.

The main purpose of an income statement is to convey details of profitability and business activities. Below, is NVS's income statement for the previous four years along with its trailing-twelve- month profit & loss.

FISCAL YEAR (BIL.)
2022 ($)
2023 ($)
2024 ($)
2025 ($)
TTM ($)
Total Revenue
51.83
51.01
51.72
56.67
56.69
Operating Revenue
50.55
49.78
50.32
54.53
54.77
Cost Of Revenue
15.49
14.41
12.83
13.70
14.32
Gross Profit
36.34
36.60
38.90
42.98
42.37
Operating Expense
27.14
26.48
24.35
25.33
25.27
Selling General And Administration
14.25
13.66
12.57
13.25
13.13
Research and Development
10.00
11.81
10.02
11.20
11.69
Operating Income
9.20
10.12
14.54
17.64
17.10
Net Non-Operating Interest Income Expense
-0.63
-0.46
-0.69
-0.98
-1.27
Other Income Expense
-0.23
-0.22
-0.31
-0.31
Other Non-Operating Income Expenses
Pre-Tax Income
8.37
9.44
13.64
16.35
15.52
Tax Provision
1.42
0.68
1.70
2.39
2.77
Net Income
6.96
14.85
11.94
13.98
12.76
Net Income Common Stockholders
6.96
14.85
11.94
13.98
12.76
Total Operating Income As Reported
9.20
10.12
14.54
17.64
17.10
Total Expenses
42.63
40.89
37.18
39.03
39.59
Net Income From Continuing And Discontinued Operation
6.96
14.85
11.94
13.98
12.76
Normalized Income
6.96
8.76
11.94
13.98
12.76
Interest Income
Interest Expense
0.84
0.87
1.01
1.14
1.39
Net Interest Income
-0.63
-0.46
-0.69
-0.98
-1.27
EBIT
9.21
10.31
14.65
17.50
16.91
EBITDA
16.39
18.83
20.71
22.82
22.45
Reconciled Cost Of Revenue
15.49
14.41
12.83
13.70
14.32
Reconciled Depreciation
7.18
8.52
6.07
5.33
5.54
Normalized EBITDA
16.39
18.83
20.71
22.82
22.45
Tax Rate For Calcs
0.00
0.00
0.00
0.00
0.24
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
0.00
BALANCE SHEET
The balance sheet is a snapshot of a companies financials during a particular period in time.

It breaks down what company owns (assets) and what a company owes (liabilities), in order to give investors an overview of its capital structure.

FISCAL YEAR (BIL.)
2022 ($)
2023 ($)
2024 ($)
2025 ($)
TTM ($)
Total Assets
117.45
99.94
102.25
110.95
122.03
Current Assets
36.91
30.48
29.70
30.46
27.35
Total Non-Current Assets
80.54
69.46
72.54
80.49
94.68
Total Liabilities Net Minority Interest
58.03
53.20
58.12
64.40
80.09
Current Liabilities
28.66
26.39
28.69
27.28
31.75
Other Non-Current Liabilities
1.58
1.19
1.04
0.96
3.90
Total Equity Gross Minority Interest
59.42
46.75
44.13
46.55
41.95
Stockholders Equity
Total Capitalization
79.59
65.10
65.41
74.06
79.03
Common Stock Equity
59.34
46.67
44.05
46.13
41.54
Net Tangible Assets
-1.60
-3.55
-7.62
-8.85
-27.30
Working Capital
8.25
4.09
1.01
3.18
-4.40
Invested Capital
85.46
71.19
73.50
79.59
88.62
Tangible Book Value
-1.60
-3.55
-7.62
-8.85
-27.30
Total Debt
27.91
26.35
31.26
35.38
49.01
Net Debt
18.60
11.13
18.00
22.02
39.46
Share Issued
2.40
2.28
2.19
2.11
1.90
Ordinary Shares Number
2.12
2.04
1.98
1.91
1.90
CASH FLOW STATEMENTS
A companies statement of cash flows gives an investor a break down of the cash inflows and outflows from a companies operations and investment activities.
FISCAL YEAR (BIL.)
2022 ($)
2023 ($)
2024 ($)
2025 ($)
TTM ($)
Cash Flow from Continuing Operating Activities
14.24
14.38
17.62
19.14
18.39
Net Income from Continuing Operations
6.96
8.76
11.94
13.97
12.75
Depreciation and Amortization
7.18
8.52
6.07
5.33
5.54
Deferred Tax
1.42
0.68
1.70
2.39
2.77
Deferred Income Tax
1.42
0.68
1.70
2.39
2.77
Stock-Based Compensation
0.82
0.89
1.04
1.10
1.14
Other Non-Cash Items
-0.06
-0.79
-0.51
0.02
-0.14
Change in Working Capital
-1.00
-0.87
-0.71
-1.58
-0.81
Change in Receivables
-1.63
-0.93
-1.12
-0.67
Changes in Account Receivables
-1.63
-0.93
-1.12
-0.67
Change in Inventory
-1.00
-0.23
0.03
-0.04
Change in Payables and Accrued Expense
0.59
-0.10
-0.27
-0.20
Change in Payable
0.59
-0.10
-0.27
-0.20
Change in Account Payable
0.59
-0.10
-0.27
-0.20
Change in Other Current Assets
-0.31
-0.50
-0.46
0.16
Change in Other Current Liabilities
1.47
1.06
0.25
-0.05
Change in Other Working Capital
Cash Flow from Continuing Investing Activities
1.47
6.54
-7.51
-4.88
-17.80
Net PPE Purchase and Sale
-1.03
-0.95
-1.28
-1.54
-1.60
Net Business Purchase and Sale
-0.90
-3.59
-3.92
-3.00
-16.04
Purchase of Business
-16.11
Net Investment Purchase and Sale
4.67
10.85
0.05
1.87
1.26
Purchase of Investment
-34.82
-0.75
-3.65
-0.30
-0.29
Sale of Investment
39.49
11.60
3.70
2.18
1.55
Net Other Investing Changes
0.19
Financing Cash Flow
-20.56
-14.28
-11.74
-14.87
0.45
Cash Flow from Continuing Financing Activities
-20.56
-17.64
-11.74
-14.87
0.45
Net Issuance Payments of Debt
-2.56
-1.93
4.39
2.43
16.45
Net Long-Term Debt Issuance
-1.35
-0.27
5.88
5.82
18.71
Long-Term Debt Issuance
0.02
19.00
Long-Term Debt Payments
-1.37
-0.28
-0.26
-0.28
-0.29
Net Short-Term Debt Issuance
-1.20
-1.66
-1.49
-3.39
-2.26
Net Common Stock Issuance
-10.65
-8.72
-8.33
-9.21
-6.86
Common Stock Issuance
Common Stock Payments
-10.65
-8.72
-8.33
-9.21
-6.86
Cash Dividends Paid
Net Other Financing Charges
0.06
0.11
-0.21
-0.27
-0.06
End Cash Position
33.72
48.68
42.44
34.71
35.48
Changes in Cash
-4.86
5.78
-1.64
-0.60
1.04
Beginning Cash Position
38.61
42.81
44.37
34.74
34.52
Capital Expenditure
-2.67
-2.93
-3.81
-3.90
-3.41
Issuance of Capital Stock
Issuance of Debt
-1.19
6.66
19.11
Repayment of Debt
-3.33
-3.50
-3.52
-4.24
-2.67
Repurchase of Capital Stock
-10.65
-8.72
-8.33
-9.21
-6.86
Free Cash Flow
11.57
11.53
13.80
15.24
14.98